A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma.
about
Interleukin 12: still a promising candidate for tumor immunotherapy?Immunocytokines and bispecific antibodies: two complementary strategies for the selective activation of immune cells at the tumor siteEnhancing the discovery and development of immunotherapies for cancer using quantitative and systems pharmacology: Interleukin-12 as a case studyThe immunocytokine NHS-IL12 as a potential cancer therapeuticNew insights into IL-12-mediated tumor suppression.Antibody-cytokine fusion proteins for treatment of cancer: engineering cytokines for improved efficacy and safety.Dual targeting strategies with bispecific antibodies.Immunocytokines: a review of molecules in clinical development for cancer therapy.Novel antibody-based proteins for cancer immunotherapy.Latent cytokines for targeted therapy of inflammatory disorders.Dendritic cell immunotherapy.Targeting Fibronectin for Cancer Imaging and Therapy.Evolution of the magic bullet: Single chain antibody fragments for the targeted delivery of immunomodulatory proteins.Antibody-cytokine fusion proteins for cancer immunotherapy: an update on recent developments.Emerging classes of armed antibody therapeutics against cancerImmunocytokines
P2860
Q26861559-4210B47E-9123-4815-BAA0-7E6CE17C51A7Q28066935-F59135CA-56A7-48CC-90A3-7276BABB2A2FQ28084489-136930B7-F1E3-4117-9F3A-92088193A3C9Q33688398-5DB60C8E-58B9-4B36-84D9-1C73711AAC4EQ34436897-B4D72778-19B8-4F0E-B4E2-8E12F43181A1Q35163167-43CEBC4D-B4F9-4E79-95A5-B66657B6DF8BQ37997559-D0B99198-6C10-4866-B554-1F9DFD417301Q38132742-30E980AF-A16C-40C4-A5C2-B93F497FB039Q38161370-9CE71F0D-A1FC-412D-B3A5-9C36305D3F45Q38167818-54299DC7-70E4-474E-9BCF-2625EBCFB7ECQ44483910-45408149-E6E9-452B-BFC2-5C75DD4475E6Q47226151-2942B0A4-B529-41D6-93C0-D4D5481E879FQ47277628-305381A4-610C-4DDB-83C8-FA40DF0339FEQ51786117-18335848-BDDA-4481-BEE8-BC8D475A95D1Q57911948-4B2DCB38-E096-4463-B256-A4A9B801CC68Q57911975-09CEC7F0-D1D3-43EF-8A0E-5FF22A6227C5
P2860
A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A phase 1 study of AS1409, a n ...... anoma or renal cell carcinoma.
@ast
A phase 1 study of AS1409, a n ...... anoma or renal cell carcinoma.
@en
A phase 1 study of AS1409, a n ...... anoma or renal cell carcinoma.
@nl
type
label
A phase 1 study of AS1409, a n ...... anoma or renal cell carcinoma.
@ast
A phase 1 study of AS1409, a n ...... anoma or renal cell carcinoma.
@en
A phase 1 study of AS1409, a n ...... anoma or renal cell carcinoma.
@nl
prefLabel
A phase 1 study of AS1409, a n ...... anoma or renal cell carcinoma.
@ast
A phase 1 study of AS1409, a n ...... anoma or renal cell carcinoma.
@en
A phase 1 study of AS1409, a n ...... anoma or renal cell carcinoma.
@nl
P2093
P2860
P1476
A phase 1 study of AS1409, a n ...... anoma or renal cell carcinoma.
@en
P2093
Duncan I Jodrell
Fredrik Erlandsson
Gary Acton
James F Spicer
Mark Harries
Michael B Jameson
Sarah M Rudman
P2860
P304
P356
10.1158/1078-0432.CCR-10-2490
P407
P577
2011-03-29T00:00:00Z